Robin Hayes
ADC189: A Promising Single-Dose Oral Therapy for Influenza Emerges from Preclinical and Phase I Trials
Seasonal influenza continues to exact a heavy toll on global health, causing an estimated 3–5 million cases of severe illness and up to 650,000 respiratory deaths annually. Existing antivirals—principally neuraminidase inhibitors (such as oseltamivir) and M2 ion-channel blockers (amantadine and rimantadine)—have demonstrable limitations. Resistance to these agents has steadily increased, and their efficacy is often modest when administered more than 48 hours after symptom onset. Moreover, the logistical challenges of multi-dose regimens hinder public health efforts during epidemics and pandemics. There is therefore an urgent need for a novel, broadly active, single-dose antiviral that can both treat and prevent influenza, including resistant and pandemic strains.
· 4 min read

